Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Research Institute Inc

Neither a doctor nor a teaching hospital

Research payments

$3,751,845

349 payments

Through program year 2025, Advanced Research Institute Inc is reported as receiving $3,751,845 in research payments, across 349 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $95,987 31
2024 Research $2,158,775 100
2023 Research $561,637 73
2022 Research $466,489 85
2021 Research $164,708 19
2020 Research $164,663 24
2019 Research $139,585 17

Breakdown

Who paid Research payments · program years 2019–2025
  1. CapsoVision, Inc. $1,661,033 44 payments
  2. Braintree Laboratories, Inc. $1,019,558 36 payments
  3. AbbVie, Inc. $496,146 165 payments
  4. Allergan Inc. $191,749 35 payments
  5. Pfizer Inc. $136,626 27 payments
  6. Amgen Inc. $101,268 6 payments
  7. Boehringer Ingelheim International GmbH $72,120 3 payments
  8. LivaNova USA, Inc. $40,224 14 payments
  9. Boehringer Ingelheim Pharma GmbH & Co.KG $16,747 5 payments
  10. Bausch Health US, LLC $16,374 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. Cln-Cvi-5794 $1,635,895 42 payments
  2. A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis $871,497 16 payments
  3. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $125,320 17 payments
  4. A Phase 2 Randomized Doubleblind Doubledummy Placebocontrolled Doseranging Dosefinding Parallel Group Study to Assess Efficacy and Safety of Pf06865571 Dgat2i Alone and When Coadministered With Pf05221304 Acci in Adult Participants With Biopsyconfirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 Or 3 $86,550 17 payments
  5. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $80,265 11 payments
  6. A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily (Virgo) $79,349 4 payments
  7. FOURIER OLE (Ph 4) $73,443 4 payments
  8. Proof of Clinical Principal in Crohn's Disease $67,906 4 payments
  9. A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) $43,957 8 payments
  10. A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) $39,042 13 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record